PubMed HealthSearch

Biomedical subjects

S A Zaki

Publications and source records attributed to S A Zaki.

8 recordsLinked to original sources

Antimicrobial activity of chloramphenicol in solid dispersion systems.

The effect of solid dispersion techniques on the antimicrobial activity of chloramphenicol has been studied and it was proven that the antimicrobial activity of chloramphenicol is not affected when the drug is present as a coprecipitate with carbowaxes (4.000, 6.000, 12.000), and PVP 11.000 and 40.000) also in fusion systems with these polymers. In contrast, the antimicrobial activity of the drug is enhanced when it is present in the from of a solid dispersion system.

Chloramphenicol

Effect of certain additives on the dissolution rate of chloramphenicol.

A study was conducted on the effect of certain additives on the dissolution rate of chloramphenicol. The effect of adsorbents, natural and synthetic surface active agents, diluents and lubricants was studied. Many of these additives increased the dissolution rate of chloramphenicol from capsules.

Alcohols

Propranolol as an adjunct to the treatment of schizophrenia.

Propranolol contributed usefully to the practical management of patients with chronic schizophrenia whose florid symptoms had not remitted with major tranquillisers. 14 patients who had received an average equivalent of 954 mg per day of chlorpromazine for 10 years were given, in addition, either propranolol or a placebo for 12 weeks. Both groups had improved by the twelfth week, but the propranolol group had improved significantly more.

Adult

Safeguards in the treatment of schizophrenia with propranolol.

Early results for an uncontrolled study of 555 patients with florid schizophrenia suggest that propranolol can be used safely in high dosage, and in a proportion of cases it appears to control schizophrenic symptoms. This method of treatment is now being submitted to controlled trial. Evdence from this uncontrolled study suggests that there was a therapeutic dose range in which symptoms steadily improved as a low dose was ineffective and a high dose, particularly if reached too rapidly, caused toxic effects. Rapid increases (400-800 mg) in the daily total intake when given in divided doses (4 to 10/day) produced gross toxic effects that included ataxia with unprotected falls, drop attacks, visual hallucinations, and confusional states. Severe toxic effects were uncommon when the dose was raised by regular, gradual increments (e.g. by 40-80 mg/day), when propranolol was given twice daily, when the dose was held steady as the patient started to improve, and when the daily total dose was reduced if the fall in pulse rate or blood pressure was excessive, or if there was evidence of toxicity. The observation of gradual, progressive improvement was the most valuable positive guide to the dose of propranolol. All schizophrenic symptoms remitted, at least temporarily, in 26 of 55 patients (in 15 of 17 patients who had been ill for less than one year and in 11 of 38 patients who had been ill for longer than a year). Patients who then stopped propranolol usually relapsed within hours or days.

Dose-Response Relationship, Drug